A Phase 1 Trial of the Wee1 Kinase Inhibitor AZD1775 in Combination With Flag Chemotherapy in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia

Trial Profile

A Phase 1 Trial of the Wee1 Kinase Inhibitor AZD1775 in Combination With Flag Chemotherapy in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 05 May 2017

At a glance

  • Drugs AZD-1775 (Primary) ; Cytarabine (Primary) ; Cytarabine (Primary) ; Filgrastim (Primary) ; Filgrastim (Primary) ; Fludarabine (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 01 May 2017 Planned initiation date changed from 30 Apr 2017 to 25 May 2017.
    • 20 Apr 2017 Planned initiation date changed from 1 Jan 2017 to 30 Apr 2017.
    • 06 Jan 2017 Status changed from not yet recruiting to withdrawn prior to enrolment as Protocol moved to Disapproved .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top